Literature DB >> 2024845

Nasal continuous positive airway pressure facilitates respiratory muscle function during sleep in severe chronic obstructive pulmonary disease.

B J Petrof1, R J Kimoff, R D Levy, M G Cosio, S B Gottfried.   

Abstract

Patients with chronic respiratory insufficiency due to severe chronic obstructive pulmonary disease (COPD) and presumed respiratory muscle fatigue may benefit from therapeutic maneuvers aimed at reducing the magnitude of inspiratory muscle effort. Recent work has demonstrated that continuous positive airway pressure (CPAP) can significantly reduce inspiratory effort and work of breathing in COPD patients with acute respiratory failure. Accordingly it was reasoned that prolonged CPAP administration may similarly reduce the work of breathing in stable COPD patients with chronic respiratory insufficiency, thereby allowing recovery from respiratory muscle fatigue. The purpose of this study was to determine the feasibility of employing nasal CPAP during sleep as a means of implementing this approach to reducing inspiratory muscle effort in such patients. Standard polysomnographic parameters were recorded during nocturnal administration of nasal CPAP in eight stable patients with severe COPD (FEV1 = 26.7 +/- 3.9% of predicted). Esophageal pressure, diaphragmatic (EMGdi) and parasternal intercostal (EMGic) electromyographic activity, arterial oxyhemoglobin saturation (SaO2), and transcutaneous PCO2 (PtcCO2) were also measured. Breathing pattern was determined by respiratory inductive plethysmography. In each patient an optimum level of nasal CPAP could be determined that produced consistent reductions in indices of inspiratory muscle effort without changing tidal volume or breathing frequency. Highly significant reductions in the tidal excursions of esophageal pressure and the pressure-time integral for the inspiratory muscles occurred at the optimum CPAP level in all patients. EMGdi and EMGic were similarly reduced. SaO2 and PtcCO2 were unaffected by CPAP. These results indicate that nasal CPAP can effectively reduce inspiratory muscle effort during sleep in patients with severe COPD.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 2024845     DOI: 10.1164/ajrccm/143.5_Pt_1.928

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  6 in total

1.  Lack of benefit of continuous positive airway pressure on lung function in patients with overlap syndrome.

Authors:  Aidan O'Brien; Kristy Whitman
Journal:  Lung       Date:  2005 Nov-Dec       Impact factor: 2.584

2.  Long-term effects of treatment with nasal continuous positive airway pressure on lung function in patients with overlap syndrome.

Authors:  Javier de Miguel; Jorge Cabello; José M F Sánchez-Alarcos; Rudolfo Alvarez-Sala; Domingo Espinós; José L Alvarez-Sala
Journal:  Sleep Breath       Date:  2002-03       Impact factor: 2.816

3.  Effect of CPAP on intrinsic PEEP, inspiratory effort, and lung volume in severe stable COPD.

Authors:  F J O'Donoghue; P G Catcheside; A S Jordan; A D Bersten; R D McEvoy
Journal:  Thorax       Date:  2002-06       Impact factor: 9.139

4.  The effect of continuous positive airway pressure on pulmonary function may depend on the basal level of forced expiratory volume in 1 second.

Authors:  Annia Schreiber; Sara Surbone; Alberto Malovini; Marco Mancini; Francesca Cemmi; Giancarlo Piaggi; Piero Ceriana; Annalisa Carlucci
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

5.  Haemodynamic effects of pressure support and PEEP ventilation by nasal route in patients with stable chronic obstructive pulmonary disease.

Authors:  N Ambrosino; S Nava; A Torbicki; G Riccardi; C Fracchia; C Opasich; C Rampulla
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

6.  Fixed-pressure nCPAP in patients with obstructive sleep apnea (OSA) syndrome and chronic obstructive pulmonary disease (COPD): a 24-month follow-up study.

Authors:  Domenico Maurizio Toraldo; Francesco De Nuccio; Giuseppe Nicolardi
Journal:  Sleep Breath       Date:  2009-09-13       Impact factor: 2.816

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.